Diffuse Alveolar Hemorrhage in Acute Myeloid Leukemia

Nanjappa, Sowmya; Jeong, Daniel; Muddaraju, Manjunath; Jeong, Katherine; Hill, E.; Greene, John N.

doi:10.1177/107327481602300310

Cited by 9 publications

(9 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nanjappa et al reported a case series of 5 patients with AML, two of whom had undergone allo-HCT, who developed DAH (100). While respiratory compromise in leukemia patients is recognized, it is likely that pulmonary hemorrhage is underestimated.…”

Section: Myelogenous Leukemiamentioning

confidence: 99%

Diffuse Alveolar Hemorrhage After Pediatric Hematopoietic Stem Cell Transplantation

et al. 2020

View full text Add to dashboard Cite

Section: Myelogenous Leukemiamentioning

confidence: 99%

Diffuse Alveolar Hemorrhage After Pediatric Hematopoietic Stem Cell Transplantation

et al. 2020

View full text Add to dashboard Cite

“…Risk factors of DAH include infections, low platelets and coagulopathy. [35] The mechanism of DAH is suggested to be due to disruption of the alveolar-capillary basement membrane caused by injury or inflammation. [36] Clinical presentation of DAH is non-specific including pyrexia, cough, hemoptysis, dyspnea and chest pain.…”

Section: Literature Reviewmentioning

confidence: 99%

“…The patients with DAH requiring ICU admission may be dealt with supplemental oxygen therapy, mechanical ventilation, reversal of coagulopathy, plasmapharesis, platelet transfusion and hemodynamic support. [35] Direct Invasion of Cancer: Lungs are also affected by direct effect of cancer, especially lung cancer. Lung cancer can invade adjacent tissues such as vascular bundle and chest wall.…”

Section: Literature Reviewmentioning

confidence: 99%

Pulmonary Complications and Critical Care in Cancer Patients

Darmi¹

2018

ijirms

View full text Add to dashboard Cite

Cancer refers to the condition where abnormal proliferation of cells occurs overriding the natural check of cell death.[1] As a normal physiological process, all cells of our body are programmed to die - called as apoptosis.[2] In cancer, the balance between cell proliferation and cell death is disrupted, resulting in uncontrolled division of cells.[3] Hence, apoptosis is an anti-cancer defense of body. In other words, carcinogenesis involves sequential genetic change that transforms normal cells to malignant cells. The cancer cells interfere with normal physiological functions and kill by invading various body organs vital for living. Cancer is a second leading cause of death worldwide, estimated to kill 9.6 million people in 2018.[4] Approximately, every sixth death is caused by cancer.[4] Globally, most common cancers are lung, breast, colorectal, prostate, skin and stomach cancers.

show abstract

“…Diffuse alveolar hemorrhage (DAH) is a potentially life-threatening pulmonary condition characterized by hypoxemia with progression to respiratory failure, rapid onset of dyspnea, and blood loss anemia [ 1 ]. While hemoptysis may be present and corroborates the diagnosis, it is absent in about half of the cases, resulting in a diagnostic challenge with variable presenting symptoms [ 2 , 3 ]. Imaging findings on chest x-ray or computed tomography (CT) scans are also non-specific, often showing diffuse bilateral alveolar opacities.…”

Section: Introductionmentioning

confidence: 99%

“…Because DAH is an under-recognized diagnosis, physicians should maintain a degree of clinical suspicion for DAH in patients with unexplained airspace opacities [ 1 ]. This is especially important in higher-risk populations such as patients with hematological malignancies, who have a propensity for thrombocytopenia, coagulopathy compounded by the use of anticoagulants, and pulmonary infections with Staphylococcus aureus , Pneumocystis jirovecii , mycobacteria, and cytomegalovirus [ 3 , 4 ]. Patients with hematological malignancies, namely acute myeloid leukemia (AML), are also at risk for drug-induced DAH due to the use of cytotoxic medications like cytarabine [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Diffuse Alveolar Hemorrhage in the Setting of Cytarabine Therapy in a Critically Ill Patient

Phan¹,

Hu²,

Hasan³

2021

Cureus

View full text Add to dashboard Cite

Diffuse alveolar hemorrhage (DAH) is a potentially life-threatening pulmonary condition characterized by hypoxemia with progression to respiratory failure, rapid onset of dyspnea, and blood loss anemia. While hemoptysis may be present and corroborates the diagnosis, it is absent in about half of the cases, resulting in a diagnostic challenge with variable presenting symptoms. Imaging findings on chest x-ray or computed tomography (CT) scans are also non-specific, often showing diffuse bilateral alveolar opacities. Because DAH is an under-recognized diagnosis, physicians should maintain a degree of clinical suspicion for DAH in patients with unexplained airspace opacities and no signs of an infectious etiology. This is especially important in higher-risk populations such as patients with hematological malignancies, who have a propensity for thrombocytopenia and coagulopathy compounded by the use of anticoagulants. Patients with hematological malignancies, namely acute myeloid leukemia (AML), are also at risk for drug-induced DAH due to the use of cytotoxic medications like cytarabine. Here, we present the case of a 48-year-old male with a past medical history of AML and myeloid sarcoma who developed shortness of breath after receiving cytarabine chemotherapy. Chest radiography revealed diffuse bilateral infiltrates. He was intubated and underwent flexible bronchoscopy, which resulted in a bloody effluent consistent with DAH. After ruling out infectious etiologies, we reached a final diagnosis of DAH and started the patient on corticosteroid therapy.

show abstract

Diffuse Alveolar Hemorrhage in Acute Myeloid Leukemia

Cited by 9 publications

References 21 publications

Diffuse Alveolar Hemorrhage After Pediatric Hematopoietic Stem Cell Transplantation

Diffuse Alveolar Hemorrhage After Pediatric Hematopoietic Stem Cell Transplantation

Pulmonary Complications and Critical Care in Cancer Patients

Diffuse Alveolar Hemorrhage in the Setting of Cytarabine Therapy in a Critically Ill Patient

Contact Info

Product

Resources

About